Esophageal Squamous Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Esophageal Squamous Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-04EMA Authorised: Loqtorzi (toripalimab) — Topalliance Biosciences Europe Limited
EMA authorised Loqtorzi (toripalimab) for nasopharyngeal carcinoma and esophageal squamous cell carcinoma.
-
EMA approval · 2026-07-13EMA Authorised: Hetronifly (serplulimab) — Accord Healthcare S.L.U.
European Medicines Agency authorises Hetronifly (serplulimab) for multiple indications including small cell lung cancer, non-small cell lung…
-
EMA approval · 2026-07-01EMA Authorised: Hetronifly (serplulimab) — Accord Healthcare S.L.U.
European Medicines Agency authorises Hetronifly (serplulimab) for multiple indications including small cell lung cancer, non-small cell lung…
-
EMA approval · 2026-04-22EMA Authorised: Loqtorzi (toripalimab) — Topalliance Biosciences Europe Limited
Loqtorzi (toripalimab) has been authorised in the European Union for nasopharyngeal carcinoma and esophageal squamous cell carcinoma. It is …
-
EMA approval · 2026-01-26EMA Authorised: Tevimbra (tislelizumab) — Beone Medicines Ireland Limited
EMA authorised Tevimbra (tislelizumab) from Beone Medicines Ireland Limited for multiple cancer indications, including esophageal squamous c…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.